Low rejection rate with high-dose ATG bolus therapy in simultaneous pancreas and kidney transplantation.
Saudek
F
F
Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Adamec
M
M
Koznarová
R
R
Jedináková
T
T
Boucek
P
P
Voska
L
L
D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology* / Q000379:methods / Q000401:mortality; D018655:Lymphocyte Count; D008297:Male; D016035:Pancreas Transplantation / Q000276:immunology* / Q000379:methods / Q000401:mortality; D010976:Platelet Count; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum